MetaCap

Cardiol Therapeutics (CRDL) vs LENZ Therapeutics (LENZ)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cardiol Therapeutics (CRDL) has outperformed LENZ Therapeutics (LENZ) over the past year, losing 11.3% versus a loss of 90.0%. Over five years, CRDL leads with a -60.1% price change compared with -95.6% for LENZ. Cardiol Therapeutics is the larger company by market cap ($110.1 million vs $93.2 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CRDL-11.35%LENZ-89.97%
+146%+22%-101%
Nov 21, 20251 yearNov 20, 2026
CRDL-57.92%LENZ-96.18%
+34%-34%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CRDL versus LENZ key metrics
MetricCRDLLENZ
Share price$0.8626$2.97
Market cap$110.14M$93.16M
1-day change-2.28%-11.23%
YTD return-9.58%-81.47%
1-year return-11.35%-89.97%
5-year return-60.06%-95.57%
EPS (TTM)$-0.24$-4.53
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$19.09M
Net income (latest FY)—$-82.13M
Gross margin—97.81%
Operating margin—-477.46%
Net margin—-430.25%
52-week high$2.34$32.13
52-week low$0.8417$2.80
Distance from 52-week high-63.14%-90.77%
Analyst consensusstrong_buynone
Avg. price target upside+874.96%+400.17%
Average volume1.20M892.30K
Shares outstanding127.69M31.42M
Employees1840
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CRDL has outperformed LENZ by 78.6 percentage points over the past year.

About Cardiol Therapeutics

CRDL stock →

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees

About LENZ Therapeutics

LENZ stock →

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees

CRDL vs LENZ FAQ

Which is bigger, Cardiol Therapeutics or LENZ Therapeutics?

Cardiol Therapeutics (CRDL) is larger, with a market capitalization of $110.14M compared with $93.16M for LENZ Therapeutics (LENZ).

Which stock has performed better over the past year, CRDL or LENZ?

CRDL returned -11.35% over the past 12 months, compared with -89.97% for LENZ (price return, excluding dividends). Past performance does not predict future results.

Are Cardiol Therapeutics and LENZ Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons